Cargando…
Cavity development: a potential biomarker for antiangiogenesis agents
Autores principales: | Jiang, Man, Zhang, Xiaochun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7082298/ https://www.ncbi.nlm.nih.gov/pubmed/32206563 http://dx.doi.org/10.21037/tlcr.2019.12.11 |
Ejemplares similares
-
Antiangiogenesis Combined with Immunotherapy to Treat Advanced Small-Cell Carcinoma of the Esophagus Resistant to Chemotherapy: According to the Guidance of Next-Generation Sequencing
por: Jiang, Man, et al.
Publicado: (2021) -
Monitoring antiangiogenesis of bevacizumab in zebrafish
por: Zhang, Jing, et al.
Publicado: (2018) -
Surrogate markers in antiangiogenesis clinical trials
por: Davis, D W, et al.
Publicado: (2003) -
Antiangiogenesis in recurrent glioblastoma: proof of principle
por: Nossek, Erez, et al.
Publicado: (2009) -
Microbiome Crosstalk in Immunotherapy and Antiangiogenesis Therapy
por: Wan, Xueting, et al.
Publicado: (2021)